Sernova: Changing the Standard of Care for Type 1 Diabetes Patients
A new approach to treating chronic diseases including Type 1 Diabetes
Sernova is developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. Further, the company’s primary focus is the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease.
About Sernova’s Cell Pouch System
The Cell Pouch system including the Cell Pouch, is a novel, proprietary, scalable, implantable macro-encapsulation device solution. It’s designed for the long-term survival as well as function of therapeutic cells. The device is also designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes. It has also been proven to provide a biologically compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown the presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.
For more information on Sernova Corp. (TSX.V: SVA, OTCQB: SEOVF) please fill out the form below.